BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

564 related articles for article (PubMed ID: 10866319)

  • 1. Construction, production, and characterization of humanized anti-Lewis Y monoclonal antibody 3S193 for targeted immunotherapy of solid tumors.
    Scott AM; Geleick D; Rubira M; Clarke K; Nice EC; Smyth FE; Stockert E; Richards EC; Carr FJ; Harris WJ; Armour KL; Rood J; Kypridis A; Kronina V; Murphy R; Lee FT; Liu Z; Kitamura K; Ritter G; Laughton K; Hoffman E; Burgess AW; Old LJ
    Cancer Res; 2000 Jun; 60(12):3254-61. PubMed ID: 10866319
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapeutic efficacy of anti-Lewis(y) humanized 3S193 radioimmunotherapy in a breast cancer model: enhanced activity when combined with taxol chemotherapy.
    Clarke K; Lee FT; Brechbiel MW; Smyth FE; Old LJ; Scott AM
    Clin Cancer Res; 2000 Sep; 6(9):3621-8. PubMed ID: 10999754
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antibody-targeted chemotherapy with the calicheamicin conjugate hu3S193-N-acetyl gamma calicheamicin dimethyl hydrazide targets Lewisy and eliminates Lewisy-positive human carcinoma cells and xenografts.
    Boghaert ER; Sridharan L; Armellino DC; Khandke KM; DiJoseph JF; Kunz A; Dougher MM; Jiang F; Kalyandrug LB; Hamann PR; Frost P; Damle NK
    Clin Cancer Res; 2004 Jul; 10(13):4538-49. PubMed ID: 15240546
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biodistribution properties of (111)indium-labeled C-functionalized trans-cyclohexyl diethylenetriaminepentaacetic acid humanized 3S193 diabody and F(ab')(2) constructs in a breast carcinoma xenograft model.
    Tahtis K; Lee FT; Smyth FE; Power BE; Renner C; Brechbiel MW; Old LJ; Hudson PJ; Scott AM
    Clin Cancer Res; 2001 Apr; 7(4):1061-72. PubMed ID: 11309358
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Radioimmunotherapy with alpha-particle emitting 213Bi-C-functionalized trans-cyclohexyl-diethylenetriaminepentaacetic acid-humanized 3S193 is enhanced by combination with paclitaxel chemotherapy.
    Kelly MP; Lee FT; Tahtis K; Smyth FE; Brechbiel MW; Scott AM
    Clin Cancer Res; 2007 Sep; 13(18 Pt 2):5604s-5612s. PubMed ID: 17875796
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Humanized anti-Lewis Y antibodies: in vitro properties and pharmacokinetics in rhesus monkeys.
    Co MS; Baker J; Bednarik K; Janzek E; Neruda W; Mayer P; Plot R; Stumper B; Vasquez M; Queen C; Loibner H
    Cancer Res; 1996 Mar; 56(5):1118-25. PubMed ID: 8640770
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cytotoxic and antitumor activity of a recombinant tumor necrosis factor-B1(Fv) fusion protein on LeY antigen-expressing human cancer cells.
    Scherf U; Benhar I; Webber KO; Pastan I; Brinkmann U
    Clin Cancer Res; 1996 Sep; 2(9):1523-31. PubMed ID: 9816329
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Transfer of chimeric receptor gene made of variable regions of tumor-specific antibody confers anticarbohydrate specificity on T cells.
    Mezzanzanica D; Canevari S; Mazzoni A; Figini M; Colnaghi MI; Waks T; Schindler DG; Eshhar Z
    Cancer Gene Ther; 1998; 5(6):401-7. PubMed ID: 9917095
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vivo biodistribution of a humanized anti-Lewis Y monoclonal antibody (hu3S193) in MCF-7 xenografted BALB/c nude mice.
    Clarke K; Lee FT; Brechbiel MW; Smyth FE; Old LJ; Scott AM
    Cancer Res; 2000 Sep; 60(17):4804-11. PubMed ID: 10987290
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chimeric (mouse/human) anti-colon cancer antibody c30.6 inhibits the growth of human colorectal cancer xenografts in scid/scid mice.
    Mount PF; Sutton VR; Li W; Burgess J; McKEnzie IF; Pietersz GA; Trapani JA
    Cancer Res; 1994 Dec; 54(23):6160-6. PubMed ID: 7954462
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enhanced efficacy of 90Y-radiolabeled anti-Lewis Y humanized monoclonal antibody hu3S193 and paclitaxel combined-modality radioimmunotherapy in a breast cancer model.
    Kelly MP; Lee FT; Smyth FE; Brechbiel MW; Scott AM
    J Nucl Med; 2006 Apr; 47(4):716-25. PubMed ID: 16595507
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting Lewis Y (Le(y)) in small cell lung cancer with a humanized monoclonal antibody, hu3S193: a pilot trial testing two dose levels.
    Krug LM; Milton DT; Jungbluth AA; Chen LC; Quaia E; Pandit-Taskar N; Nagel A; Jones J; Kris MG; Finn R; Smith-Jones P; Scott AM; Old L; Divgi C
    J Thorac Oncol; 2007 Oct; 2(10):947-52. PubMed ID: 17909358
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chimeric anti-ganglioside GM2 antibody with antitumor activity.
    Nakamura K; Koike M; Shitara K; Kuwana Y; Kiuragi K; Igarashi S; Hasegawa M; Hanai N
    Cancer Res; 1994 Mar; 54(6):1511-6. PubMed ID: 8137257
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Binding and functional properties of a mouse-human chimeric monoclonal antibody of the human IgG1 subclass with specificity for human carcinomas.
    Liao SK; Horton L; Flahart RE; O'Rear L; Crumpacker D; Imbaratto JW; Yannelli JR; Robinson RR; Oldham RK
    Hum Antibodies Hybridomas; 1990; 1(2):66-76. PubMed ID: 2103354
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Lewis-Y carbohydrate antigen is expressed by many human tumors and can serve as a target for genetically redirected T cells despite the presence of soluble antigen in serum.
    Westwood JA; Murray WK; Trivett M; Haynes NM; Solomon B; Mileshkin L; Ball D; Michael M; Burman A; Mayura-Guru P; Trapani JA; Peinert S; Hönemann D; Miles Prince H; Scott AM; Smyth MJ; Darcy PK; Kershaw MH
    J Immunother; 2009 Apr; 32(3):292-301. PubMed ID: 19242371
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Generation of anti-idiotype antibodies for application in clinical immunotherapy laboratory analyses.
    Liu Z; Panousis C; Smyth FE; Murphy R; Wirth V; Cartwright G; Johns TG; Scott AM
    Hybrid Hybridomics; 2003 Aug; 22(4):219-28. PubMed ID: 14511567
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A neutralizing anti-fibroblast growth factor (FGF) 8 monoclonal antibody shows anti-tumor activity against FGF8b-expressing LNCaP xenografts in androgen-dependent and -independent conditions.
    Maruyama-Takahashi K; Shimada N; Imada T; Maekawa-Tokuda Y; Ishii T; Ouchi J; Kusaka H; Miyaji H; Akinaga S; Tanaka A; Shitara K
    Prostate; 2008 May; 68(6):640-50. PubMed ID: 18213631
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tumor growth suppression by a mouse/human chimeric anti-CEA antibody and lymphokine-activated killer cells in vitro and in SCID mouse xenograft model.
    Senba T; Kuroki M; Arakawa F; Yamamoto T; Kuwahara M; Haruno M; Ikeda S; Matsuoka Y
    Anticancer Res; 1998; 18(1A):17-24. PubMed ID: 9568050
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The production and preclinical characterization of a chimeric anti-breast-cancer antibody, cBC2.
    Sutton VR; Burgess J; Pietersz GA; Li WJ; McKenzie IF; Trapani JA
    Ther Immunol; 1994 Apr; 1(2):83-93. PubMed ID: 7584487
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterization of two human small cell lung carcinoma-reactive monoclonal antibodies generated by a novel immunization approach.
    Tong AW; Lee J; Stone MJ
    Cancer Res; 1984 Nov; 44(11):4987-92. PubMed ID: 6207911
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.